RS53623B1 - Estri metronidazola za tretiranje rozacee - Google Patents

Estri metronidazola za tretiranje rozacee

Info

Publication number
RS53623B1
RS53623B1 RS20140559A RSP20140559A RS53623B1 RS 53623 B1 RS53623 B1 RS 53623B1 RS 20140559 A RS20140559 A RS 20140559A RS P20140559 A RSP20140559 A RS P20140559A RS 53623 B1 RS53623 B1 RS 53623B1
Authority
RS
Serbia
Prior art keywords
acid
compound
formula
compound according
pharmaceutically acceptable
Prior art date
Application number
RS20140559A
Other languages
English (en)
Serbian (sr)
Inventor
Jean-Guy Boiteau
Jean-Michel Linget
Original Assignee
Galderma Research & Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research & Development filed Critical Galderma Research & Development
Publication of RS53623B1 publication Critical patent/RS53623B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RS20140559A 2010-06-29 2011-06-29 Estri metronidazola za tretiranje rozacee RS53623B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1055241A FR2961809B1 (fr) 2010-06-29 2010-06-29 Esters de metronidazole pour traiter la rosacee
PCT/EP2011/060923 WO2012001053A1 (en) 2010-06-29 2011-06-29 Metronidazole esters for treating rosacea

Publications (1)

Publication Number Publication Date
RS53623B1 true RS53623B1 (sr) 2015-04-30

Family

ID=42790955

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20140559A RS53623B1 (sr) 2010-06-29 2011-06-29 Estri metronidazola za tretiranje rozacee

Country Status (23)

Country Link
US (1) US8802710B2 (https=)
EP (1) EP2588462B1 (https=)
JP (1) JP2013529667A (https=)
KR (1) KR20130088135A (https=)
CN (1) CN102958920A (https=)
AR (1) AR081783A1 (https=)
AU (1) AU2011273498A1 (https=)
BR (1) BR112012032490A2 (https=)
CA (1) CA2801977A1 (https=)
CY (1) CY1115622T1 (https=)
DK (1) DK2588462T3 (https=)
ES (1) ES2518119T3 (https=)
FR (1) FR2961809B1 (https=)
HR (1) HRP20140966T1 (https=)
IN (1) IN2013CN00515A (https=)
MX (1) MX2012014632A (https=)
PL (1) PL2588462T3 (https=)
PT (1) PT2588462E (https=)
RS (1) RS53623B1 (https=)
RU (1) RU2013103693A (https=)
SI (1) SI2588462T1 (https=)
SM (1) SMT201400174B (https=)
WO (1) WO2012001053A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9715942B2 (en) 2015-06-09 2017-07-25 International Business Machines Corporation Built-in self-test (BIST) circuit and associated BIST method for embedded memories
CN120309545A (zh) * 2024-01-15 2025-07-15 中国药科大学 一种甲硝唑衍生物、制备方法及在药物制备中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127274A3 (en) * 1983-03-25 1987-05-20 The Upjohn Company Esters of metronidazole and compositions containing them
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
US8853247B2 (en) * 2007-11-02 2014-10-07 Nektar Therapeutics Oligomer-nitroimidazole anti-infective conjugates

Also Published As

Publication number Publication date
FR2961809B1 (fr) 2012-07-06
SMT201400174B (it) 2015-01-15
FR2961809A1 (fr) 2011-12-30
AR081783A1 (es) 2012-10-17
EP2588462B1 (en) 2014-08-13
CA2801977A1 (en) 2012-01-05
CN102958920A (zh) 2013-03-06
IN2013CN00515A (https=) 2015-07-03
DK2588462T3 (da) 2014-11-03
US20130217740A1 (en) 2013-08-22
MX2012014632A (es) 2013-02-07
AU2011273498A1 (en) 2013-01-10
BR112012032490A2 (pt) 2016-12-13
KR20130088135A (ko) 2013-08-07
JP2013529667A (ja) 2013-07-22
HRP20140966T1 (hr) 2015-01-02
PT2588462E (pt) 2014-10-30
WO2012001053A1 (en) 2012-01-05
EP2588462A1 (en) 2013-05-08
PL2588462T3 (pl) 2015-03-31
CY1115622T1 (el) 2017-01-04
SI2588462T1 (sl) 2015-02-27
ES2518119T3 (es) 2014-11-04
US8802710B2 (en) 2014-08-12
RU2013103693A (ru) 2014-08-10

Similar Documents

Publication Publication Date Title
US20250195526A1 (en) Pharmaceutical compositions comprising sepiapterin and uses thereof
AU2019277372B2 (en) Pharmaceutically acceptable salts of sepiapterin
EP2588463B1 (en) Metronidazole esters for treating rosacea
Şenol et al. Synthesis of nitrogen-containing oleanolic acid derivatives as carbonic anhydrase and acetylcholinesterase inhibitors
WO2017147161A1 (en) Treatment of dermatological disorders or conditions
BRPI0815455B1 (pt) compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo
TW201331202A (zh) ［１，２，４］三唑并吡啶及其作為磷酸二酯酶抑制劑之用途
RS53623B1 (sr) Estri metronidazola za tretiranje rozacee
US8796325B2 (en) Metronidazole esters for treating rosacea
EP2522394B1 (en) Substituted phosphonates and their use decreasing amyloid aggregates
US7074938B2 (en) Method for the synthesis of soritin compounds
WO2022264142A1 (en) Benzothiazole based compounds and use thereof as protein disulphide isomerase inhibitors
WO2025222091A9 (en) Poly inflammatory kinase inhibitors and pharmaceutical compositions
BR112020003865B1 (pt) Composições farmacêuticas compreendendo sepiapterina e usos das mesmas